EP4456983A4 - Pharmazeutische zusammensetzungen mit macitentan als wirkstoff und anderen relevanten hilfsstoffen - Google Patents

Pharmazeutische zusammensetzungen mit macitentan als wirkstoff und anderen relevanten hilfsstoffen

Info

Publication number
EP4456983A4
EP4456983A4 EP21970145.5A EP21970145A EP4456983A4 EP 4456983 A4 EP4456983 A4 EP 4456983A4 EP 21970145 A EP21970145 A EP 21970145A EP 4456983 A4 EP4456983 A4 EP 4456983A4
Authority
EP
European Patent Office
Prior art keywords
active ingredient
pharmaceutical compositions
compositions containing
relevant excipients
containing macitentan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21970145.5A
Other languages
English (en)
French (fr)
Other versions
EP4456983A1 (de
Inventor
Abdulhaluk Sancak
Goren Ayse Figen Onuk
Hakan Gurpinar
Asiye Sezgin
Azmatullah Ansari
Gizem Alkan
Koray Yilmaz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adalvo Ltd
Humanis Saglik AS
Original Assignee
Adalvo Ltd
Humanis Saglik AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adalvo Ltd, Humanis Saglik AS filed Critical Adalvo Ltd
Publication of EP4456983A1 publication Critical patent/EP4456983A1/de
Publication of EP4456983A4 publication Critical patent/EP4456983A4/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
EP21970145.5A 2021-12-30 2021-12-30 Pharmazeutische zusammensetzungen mit macitentan als wirkstoff und anderen relevanten hilfsstoffen Pending EP4456983A4 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/TR2021/051618 WO2023128898A1 (en) 2021-12-30 2021-12-30 Pharmaceutical compositions comprising macitentan as active ingredient and other relevant excipients

Publications (2)

Publication Number Publication Date
EP4456983A1 EP4456983A1 (de) 2024-11-06
EP4456983A4 true EP4456983A4 (de) 2025-09-17

Family

ID=87000088

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21970145.5A Pending EP4456983A4 (de) 2021-12-30 2021-12-30 Pharmazeutische zusammensetzungen mit macitentan als wirkstoff und anderen relevanten hilfsstoffen

Country Status (2)

Country Link
EP (1) EP4456983A4 (de)
WO (1) WO2023128898A1 (de)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107913256A (zh) * 2016-10-08 2018-04-17 郑州泰丰制药有限公司 一种治疗肺动脉高压的马西替坦口腔崩解片及其制备方法
WO2018153925A1 (en) * 2017-02-22 2018-08-30 Amneal Pharmaceuticals Company Gmbh Stable pharmaceutical compositions comprising macitentan

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109260163A (zh) * 2018-10-07 2019-01-25 威海云睿信息科技有限公司 一种马西替坦片剂组合物
EP4417254A3 (de) * 2019-07-05 2025-03-05 Tecnimede, Sociedade Técnico-Medicinal, SA Komprimierte macitentanzusammensetzungen, verfahren und verwendungen davon
CN112336693A (zh) * 2020-09-29 2021-02-09 南京斯泰尔医药科技有限公司 一种快速控制和评价马昔腾坦片释放的方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107913256A (zh) * 2016-10-08 2018-04-17 郑州泰丰制药有限公司 一种治疗肺动脉高压的马西替坦口腔崩解片及其制备方法
WO2018153925A1 (en) * 2017-02-22 2018-08-30 Amneal Pharmaceuticals Company Gmbh Stable pharmaceutical compositions comprising macitentan

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2023128898A1 *

Also Published As

Publication number Publication date
EP4456983A1 (de) 2024-11-06
WO2023128898A1 (en) 2023-07-06

Similar Documents

Publication Publication Date Title
EP4149470A4 (de) Pharmazeutische formulierungen und verwendungen davon
ES2850277R1 (es) Composiciones de administración farmacéutica y usos de las mismas
EP4221690A4 (de) Pharmazeutische zusammensetzungen
EP4271386A4 (de) Pharmazeutische zusammensetzungen mit meloxicam
EP4146247A4 (de) Pharmazeutische und kosmetische zusammensetzungen mit sekretomen
AR022589A1 (es) UNA CÁPSULA QUE COMPRENDE UNA COMPOSICIoN FARMACÉUTICA ESPONTÁNEAMENTE DISPERSABLE PARA LA ADMINISTRACIoN ORAL, UNA COMPOSICIoN FARMACÉUTICA ESPONTÁNEAMENTE DISPERSABLE PARA LA ADMINISTRACIoN ORAL Y EL USO PARA LA PREPARACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DEL CÁNCER
EP4135699A4 (de) Pharmazeutische zusammensetzungen
MX2020004107A (es) Tabletas de deferiprona de liberacion retrasada y metodos de uso de las mismas.
EP4398909A4 (de) Pharmazeutische zusammensetzung und verwendung davon
EP4267140A4 (de) Antikörper-wirkstoff-konjugate, pharmazeutische zusammensetzungen und therapeutische anwendungen
EP4314033A4 (de) Fusionsproteine, pharmazeutische zusammensetzungen und therapeutische anwendungen
EP3819298C0 (de) Verbindung mit trka hemmender wirkung und pharmazeutische zusammensetzung zur vorbeugung oder linderung von schmerzen damit als wirkstoff
EP4538270A4 (de) Neuartige verbindung und pharmazeutische zusammensetzung damit als wirkstoff
EP4201941A4 (de) Pyrazolborsäureverbindung, pharmazeutische zusammensetzung damit und verwendungen davon
EP4400094A4 (de) Pharmazeutische zusammensetzung mit grosser physiologisch aktiver substanz und hilfsstoff
EP4436580A4 (de) Pharmazeutische zusammensetzung und verwendung davon
EP4456983A4 (de) Pharmazeutische zusammensetzungen mit macitentan als wirkstoff und anderen relevanten hilfsstoffen
EP4171544A4 (de) Pharmazeutische formulierungen von griseofulvin zur langfristigen okularen verabreichung
EP4211119A4 (de) 2-aminochinazoline als lrrk2-hemmer, pharmazeutische zusammensetzungen und verwendungen davon
EP4197560A4 (de) Pharmazeutische zusammensetzung mit einem persistenten triple-aktivator-konjugat als wirkstoff
MX391191B (es) Composiciones de liberación extendida de onapristona y métodos.
EP4110780A4 (de) 1,3,4oxadiazolderivatverbindungen als histondeacetylase-6-hemmer und pharmazeutische zusammensetzung damit
EP4225278A4 (de) Pharmazeutische zusammensetzung aus siglec-bindenden mitteln
ATE442864T1 (de) Pharmazeutische zusammensetzung mit einem organopolysiloxan-elastomer und einem lösungsmittel-aktivwirkstoff
AR037496A1 (es) Uso novedoso del 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y sus sales fisiologicamente aceptables

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20240722

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20250819

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 9/12 20060101AFI20250812BHEP

Ipc: A61P 11/00 20060101ALI20250812BHEP

Ipc: A61K 9/20 20060101ALI20250812BHEP

Ipc: A61K 31/506 20060101ALI20250812BHEP

Ipc: A61K 9/28 20060101ALN20250812BHEP